SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
NCT ID: NCT05689619
Last Updated: 2023-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
70 participants
INTERVENTIONAL
2023-09-01
2027-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be randomized 1:1 to silibinin 1 g/day taken orally in comparison with oral placebo 1 g/day. A contrast-enhanced brain MRI will be performed every 8 weeks to evaluate intracranial local and distance recurrence
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Silibinin
Silibinin (STAT3 inhibitor) 1 g/day taken orally every day
Silibinin
Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
Placebo
Placebo 1 g/day taken orally every day
Placebo
Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Silibinin
Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
Placebo
Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Single BM (maximum diameter of 3 cm) on MRI before surgery
* Complete surgical resection (MRI-verified within 14 days prior randomization)
* pSTAT3 score in reactive astrocytes of peritumoral tissue confirmed by local or central assessment
* patient must have recovered from the effects of surgery, including post-operative infection, suture/stample removal from brain surgery and wound healing before randomization
* ≥ 18 - 70 years of age
* Karnofsky performance status ≥ 70 at assessment ≤ 14 days prior to randomization
* patient has adequate bone marrow, renal, and hepatic function ≤ 21 days prior to randomization as follows:
1. absolute neutrophil count (ANC) ≥ 1500/mm3
2. platelets ≥ 100000/ mm3
3. Hemoglobin ≥ 9.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin ≥ 9.0 g/dl is acceptable)
4. renal function: calculated creatinine clearance ≥ 30 ml/min by the Cockcroft-Gault formula
5. hepatic function: total bilirubin ≤ 1.5 times upper limit of normal (ULN), aspartate aminotransferase (AST), and alanine transferase (ALT) ≤ 3 times ULN. Subjects with Gilbert's syndrome documented in medical history may be enrolled if total bilirubin is \< 3 times ULN
* Electrocardiogram (ECG) without evidence of acute cardiac ischemia ≤ 21 days prior to randomization
* Female subject of childbearing potential (i.e. those who are not postmenopausal for at least 1 year or surgically sterile by bilateral salpingectomy, bilateral oophorectomy or hysterectomy) should practice at least one accepted method of birth control listed below during study entry, for the entire duration of the study and for at least 6 months after treatment with silibinin has ended. Male subjects should practice at least one accepted method of birth control listed below during study entry, for the entire duration of the study and for at least 6 months after treatment with silibinin has ended. If using a condom, practice at least one other method of birth control listed below during the study for at least 6 months after silibinin treatment:
* Combined (estrogen and progesterone contained) hormonal contraception (oral, intravaginal, transdermal) associated with the inhibition of ovulation
* Progesterone-only hormonal contraception (oral, intravaginal, transdermal) associated with the inhibition of ovulation
* Bilateral tubal occlusion/ligation
* True abstinence: refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject
* A vasectomized male subject or a vasectomized partner of a female subject
* Intrauterine device, IUD (females)
* Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream) unless not deemed acceptable as highly effective contraception by local regulations
* Women of child-bearing potential must have a negative pregnancy test (urine o serum) within 7 days prior the randomization
* Must voluntarily sign and date informed consent form, for both tumor tissue biomarker testing and study participation, approved by an Independent Ethic Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures
Exclusion Criteria
* Incomplete surgical resection and/or diameters \> 3 centimeters of brain metastasis before surgery
* Brain metastases that previously received any type of radiation therapy
* Progressive systemic disease requiring a change of the antineoplastic therapy
* Prior invasive malignancy (except for non-melanomatous skin cancer, oral cavity, or cervix) unless disease free for ≥ 2 years
* Prior, concomitant, or planned treatment with experimental agents
* Patients has had major immunologic reaction
* Patient has had a history of hypersensitivity to silibinin or excipient
* Patient is unsuitable to receive steroids
* Patient is a lactating or pregnant female
* Severe, active co-morbidity, defined as follows:
* Severe hepatic impairment (Child-Pugh C or higher \[score of 10 or higher\]); subject with mild or moderate hepatic impairment (Child-Pugh score of 5-9) may be eligible for treatment
* Unstable angina and/or congestive heart failure within the last 6 months
* Transmural myocardial infarction within the last 6 months
* Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations ≥ 2 mm using the analysis of an EKG performed within 21 days prior to enrollment
* New York Heart Association grade2 or greater congestive heart failure requiring hospitalization within 12 months prior to enrollment
* History of stroke, cerebral vascular accident or transient ischemic attack within 6 months
* Serious and inadequately controlled cardiac arrhythmia
* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of enrollment
* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of enrollment
* Subject with clinically defined Acquired Immune-Deficiency Syndrome (AIDS)-defining illness. This is necessary to ensure subjects are likely to be able to receive silibinin plus standard of care according to the systemic disease
* Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the Investigator may put the subject at high risk of toxicity
* Any other major medical illnesses or psychiatric impairments that in the Investigator's opinion will prevent administrations or completion of protocol therapy
* Patient treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study except intra-operative therapy to guide resection or experimental imaging without therapeutic intent
* Inability to undergo contrast-enhanced MRI scans
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
A.O.U. Città della Salute e della Scienza
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alessia Pellerino
M.D., Ph.D.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unità Operativa di Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino di Genova
Genova, , Italy
Neurosurgery Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina
Messina, , Italy
Institute of Neurosurgery, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Catholic University
Rome, , Italy
Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute
Rome, , Italy
Precision Medicine in Breast Cancer Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, , Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Turin, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Elisa Bennicelli, M.D.
Role: primary
Filippo Flavio Angileri
Role: primary
Alessandro Olivi
Role: primary
Andrea Pace
Role: primary
Alessandra Fabi
Role: primary
Alessia Pellerino, M.D., Ph.D
Role: primary
Pierangela Botta
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, Doglio L, Martinez L, Martinez-Saez E, Ramon Y Cajal S, Megias D, Hernandez-Encinas E, Blanco-Aparicio C, Martinez L, Zarzuela E, Munoz J, Fustero-Torre C, Pineiro-Yanez E, Hernandez-Lain A, Bertero L, Poli V, Sanchez-Martinez M, Menendez JA, Soffietti R, Bosch-Barrera J, Valiente M. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018 Jul;24(7):1024-1035. doi: 10.1038/s41591-018-0044-4. Epub 2018 Jun 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SILMET_0107665
Identifier Type: -
Identifier Source: org_study_id